Cargando…

Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model

Evaluation of a potential risk of metabolic drug–drug interactions (DDI) is of high importance in the clinical setting. In this study, a physiologically based pharmacokinetic (PBPK) model was developed for oxycodone and its two primary metabolites, oxymorphone and noroxycodone, in order to assess di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marsousi, N, Daali, Y, Rudaz, S, Almond, L, Humphries, H, Desmeules, J, Samer, C F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288002/ https://www.ncbi.nlm.nih.gov/pubmed/25518025 http://dx.doi.org/10.1038/psp.2014.49

Ejemplares similares

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene–Drug–Drug Interactions
por: Storelli, Flavia, et al.
Publicado: (2019)

Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail
por: Bosilkovska, Marija, et al.
Publicado: (2019)

Applications of CYP450 Testing in the Clinical Setting
por: Samer, C. F., et al.
Publicado: (2013)

CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients
por: Stamer, Ulrike M., et al.
Publicado: (2013)

Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol
por: Rodieux, Frédérique, et al.
Publicado: (2023)

Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6‐hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots
por: Magliocco, Gaëlle, et al.
Publicado: (2022)

CYP450 Genotype—Phenotype Concordance Using the Geneva Micrococktail in a Clinical Setting
por: Ing Lorenzini, Kuntheavy, et al.
Publicado: (2021)

The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?
por: Magliocco, Gaëlle, et al.
Publicado: (2021)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
por: Fuhr, Laura Maria, et al.
Publicado: (2021)

Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics
por: Lenoir, Camille, et al.
Publicado: (2021)

Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity
por: Bouatou, Yassine, et al.
Publicado: (2014)

Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers
por: Ancrenaz, Virginie, et al.
Publicado: (2013)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers
por: Coyle, D. Tyler, et al.
Publicado: (2020)

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
por: Kim, Se-Hyung, et al.
Publicado: (2018)

Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting
por: Lenoir, Camille, et al.
Publicado: (2022)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
por: Grzegorzewski, Jan, et al.
Publicado: (2022)

Practice of CYP450 genotyping and phenotyping in children in a real-life setting
por: Rodieux, Frédérique, et al.
Publicado: (2023)

META-ANALYSIS OF CYP2D6 METABOLIZER PHENOTYPE AND METOPROLOL PHARMACOKINETICS
por: Blake, CM, et al.
Publicado: (2013)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network
por: Feick, Denise, et al.
Publicado: (2023)

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism
por: Deodhar, Malavika, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
por: Ueno, Takashi, et al.
Publicado: (2021)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?
por: Yasar, Umit
Publicado: (2018)

Amenamevir: Studies of Potential CYP2C8‐ and CYP2B6‐Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers
por: Dennison, Jeremy, et al.
Publicado: (2018)

Association of CYP2D6 genotype predicted phenotypes with oxycodone requirements and side effects in children undergoing surgery
por: Merchant, Soroush, et al.
Publicado: (2022)

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone
por: Rüdesheim, Simeon, et al.
Publicado: (2022)

Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity
por: Magliocco, Gaëlle, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
por: Rüdesheim, Simeon, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and Competitive Inhibition
por: Long, Tao, et al.
Publicado: (2021)

The Chinese herb Styrax triggers pharmacokinetic herb-drug interactions via inhibiting intestinal CYP3A
por: Zhang, Feng, et al.
Publicado: (2022)

Pharmacokinetic interaction between rhynchopylline and pellodendrine via CYP450 enzymes and P-gp
por: Meng, Qingzhen, et al.
Publicado: (2021)

Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
por: Kneller, Lisa Alina, et al.
Publicado: (2021)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

“Late” Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn
por: Passia, Evangelia, et al.
Publicado: (2017)

Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
por: Chung, Woo Kyung, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
por: Marok, Fatima Zahra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vtq69b2cmeo5n2tnksqln1539r